

FOI 3290

11<sup>th</sup> September 2025

**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

I am conducting analysis on the treatment of haematology in secondary care and kindly request your help.

I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of April 2025 to the end of June 2025, or the latest three-month period for which data is available. Please include data for all hospitals in the Health and Social Care Trust.

**NON-HODGKIN’S LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) AND ACUTE MYELOID LEUKAEMIA (AML)**

**Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?**

**Response:**

Please see below data for the period 10<sup>th</sup> June 2025 to 9<sup>th</sup> September 2025.

| Name of medicine              | Number patients treated |
|-------------------------------|-------------------------|
| 1.1 Acalabrutinib (Calquence) | 27                      |
| 1.2 Ibrutinib (Imbruvica)     | 9                       |
| 1.3 Pirtobrutinib (Jaypirca)  | 0                       |
| 1.4 Venetoclax (Venclyxto)    | 8                       |
| 1.5 Zanubrutinib (Brukinsa)   | 4                       |
| 1.6 Rituximab                 | 28                      |
| 1.7 Obinutuzumab (Gazyvaro)   | 14                      |

**Q2. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the**

**following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available?**

**Response:**

Unable to answer as data currently held cannot be linked to single diagnosis

| Name of medicine              | Number patients treated |
|-------------------------------|-------------------------|
| 2.1 Acalabrutinib (Calquence) |                         |
| 2.2 Ibrutinib (Imbruvica)     |                         |
| 2.3 Pirtobrutinib (Jaypirca)  |                         |
| 2.4 Venetoclax (Venclyxto)    |                         |
| 2.5 Zanubrutinib (Brukinsa)   |                         |
| 2.6 Obinutuzumab (Gazyvaro)   |                         |
| 2.7 Rituximab                 |                         |
| 2.8 Bendamustine              |                         |
| 2.9 Chlorambucil              |                         |
| 2.10 Fludarabine              |                         |
| 2.11 Cyclophosphamide         |                         |

**Q3. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?**

**Response:**

Unable to answer as data currently held cannot be linked to single diagnosis

| Name of monotherapy or combination         | Number patients treated |
|--|-------------------------|
| 3.1 Ibrutinib + venetoclax                 |                         |
| 3.2 Obinutuzumab + venetoclax              |                         |
| 3.3 Zanubrutinib monotherapy / maintenance |                         |
| 3.4 Ibrutinib monotherapy / maintenance    |                         |
| 3.5 Venetoclax monotherapy                 |                         |
| 3.6 Venetoclax + rituximab                 |                         |

**Q4. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?**

**Response:**

Unable to answer as data currently held cannot be linked to single diagnosis

| Name of monotherapy or combination | Number patients treated |
|------------------------------------|-------------------------|
| 4.1 Acalabrutinib                  |                         |
| 4.2 Ibrutinib                      |                         |
| 4.3 Zanubrutinib                   |                         |

**Q5. How many patients with Acute Myeloid Leukaemia – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?**

**Response:**

Unable to answer as data currently held cannot be linked to single diagnosis

| Name of medicine           | Number patients treated |
|----------------------------|-------------------------|
| 5.1 Azacitidine            |                         |
| 5.2 Cytarabine             |                         |
| 5.3 Venetoclax (Venclyxto) |                         |

**Q6. How many patients with Acute Myeloid Leukaemia were treated with the following medicines in combination, in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?**

**Response:**

Unable to answer as data currently held cannot be linked to single diagnosis

| Name of combination  | Number patients treated |
|--|-------------------------|
| 6.1 Venetoclax + Azacitidine ( <i>with or without posaconazole</i> )     |                         |
| 6.2 Venetoclax + Cytarabine ( <i>inc. V + LDAC, V + ARAC, V+ ARA-C</i> ) |                         |

**Q7. How many patients with Multiple Myeloma were treated with the following medicines in combination, in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?**

**Response:**

Unable to answer as data currently held cannot be linked to single diagnosis

| Name of medicine   | Number patients treated |
|--|-------------------------|
| 7.1 Daratumumab + Bortezomib + Dexamethasone [DVd]                   |                         |
| 7.2 Daratumumab + Bortezomib + Thalidomide + Dexamethasone [DVTd]    |                         |
| 7.3 Daratumumab + Lenalidomide + Dexamethasone [DRD]                 |                         |
| 7.4 Lenalidomide + Dexamethasone [Rd]                                |                         |
| 7.5 Lenalidomide (monotherapy)                                       |                         |
| 7.6 Carfilzomib + Lenalidomide + Dexamethasone [KRd]                 |                         |
| 7.7 Elotuzumab + Lenalidomide + Dexamethasone [ERd]                  |                         |
| 7.8 Ixazomib + Lenalidomide + Dexamethasone [IRd]                    |                         |
| 7.9 Belantamab Mafodotin (monotherapy)                               |                         |
| 7.10 Belantamab Mafodotin + Bortezomib + Dexamethasone [BVd]         |                         |
| 7.11 Any other combination containing Lenalidomide (please specify): |                         |

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)